Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/19/2021 02/22/2021 02/23/2021 02/24/2021 02/25/2021 Date
162.98(c) 161.87(c) 160.44(c) 162.59(c) 162.76(c) Last
8 190 883 6 447 105 7 042 829 10 286 107 9 719 715 Volume
-1.67% -0.68% -0.88% +1.34% +0.10% Change
More quotes
Financials (USD)
Sales 2021 91 562 M - -
Net income 2021 22 357 M - -
Net cash position 2021 3 693 M - -
P/E ratio 2021 19,7x
Yield 2021 2,62%
Sales 2022 95 128 M - -
Net income 2022 21 198 M - -
Net cash position 2022 13 164 M - -
P/E ratio 2022 19,3x
Yield 2022 2,71%
Capitalization 428 B 428 B -
EV / Sales 2021 4,63x
EV / Sales 2022 4,36x
Nbr of Employees 134 500
Free-Float 83,4%
More Financials
Company
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... 
Sector
Pharmaceuticals
Calendar
02/25 | 10:45amPresentation
More about the company
Notations Surperformance© of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
All news about JOHNSON & JOHNSON
02/25ASTRAZENECA : Vaccine makers defend patent rights, oppose export bans before EU ..
RE
02/25JOHNSON & JOHNSON : Over 41,000 Health Care Workers Inoculated
AQ
02/25JOHNSON & JOHNSON : Janssen Announces Submission of Supplemental New Drug Applic..
AQ
02/25DRIVING CHANGE : How Johnson & Johnson Is Using Mobile Healthcare to Help Addres..
PU
02/24Stocks End Higher After Powell's Reassurance Fed Will Support Growth
MT
02/24CLOSE UPDATE : Stocks End Higher Amid Powell's Reassurance on Maintaining Econom..
MT
02/24JOHNSON & JOHNSON : Janssen Says ViiV Submits SNDA for Expanded Use of Cabenuva
DJ
02/24JOHNSON & JOHNSON : COVID-19 Vaccine Candidate Endorsed by FDA Staff Ahead of Ke..
MT
02/24JOHNSON & JOHNSON : J&J's Covid-19 Vaccine Is Safe and Effective, FDA Says--Upda..
DJ
02/24MIDDAY REPORT : Wall Street Recovers Midday, Bond Yields Rise Further Amid Powel..
MT
02/24US takes 1st step toward approving single-dose Covid-19 vaccine
AQ
02/24JOHNSON & JOHNSON : FDA Says Johnson & Johnson's Covid Vaccine Has a 'Favorable ..
DJ
02/24FDA says Johnson & Johnson COVID-19 vaccine safe, has few side effects
AQ
02/24JOHNSON & JOHNSON : Single-Dose COVID-19 Vaccine Found to be Safe, Poised for Em..
MT
02/24JOHNSON & JOHNSON : FDA Says Johnson & Johnson's Covid Vaccine Has a 'Favorable ..
DJ
More news
News in other languages on JOHNSON & JOHNSON
02/25Tokyo retrouve du tonus dans le sillage de Wall Street
02/24De nouveau rassurée sur les taux, Wall Street rebondit, record pour le Dow Jo..
02/24MÄRKTE USA/Wall Street mit deutlichen Aufschlägen - Nasdaq +1,0%
02/24CORONAVIRUS : la FDA confirme l'efficacité du vaccin de Johnson & Johnson
02/24MÄRKTE USA/Börsen mit Aufschlägen - auch Nasdaq im Plus
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 180,51 $
Last Close Price 162,76 $
Spread / Highest target 23,5%
Spread / Average Target 10,9%
Spread / Lowest Target -6,00%
EPS Revisions
Managers and Directors
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.42%427 844
ROCHE HOLDING AG-3.87%281 904
NOVARTIS AG-5.51%197 388
ABBVIE INC.0.17%189 532
MERCK & CO., INC.-8.78%188 791
PFIZER INC.-8.31%188 042